ArticleGene therapy2009
Purification of recombinant baculoviruses for gene therapy using membrane processes.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- A Combined Ultrafiltration/Diafiltration Process for the Purification of Oncolytic Measles Virus.Membranes · 2022Article
- Bioanalytics for Influenza Virus-Like Particle Characterization and Process Monitoring.Frontiers in bioengineering and biotechnology · 2022Article
- Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography.Biotech (Basel (Switzerland)) · 2021Article
- Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.Journal of pharmaceutical analysis · 2020Review
- Tangential Flow Filtration for the Concentration of Oncolytic Measles Virus: The Influence of Filter Properties and the Cell Culture Medium.Membranes · 2019Article
- Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles.Bioconjugate chemistry · 2016Article
- Purification of baculovirus vectors using heparin affinity chromatography.Molecular therapy. Methods & clinical development · 2016Article
- Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials.Molecular therapy. Methods & clinical development · 2016Review
- Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages.Human vaccines & immunotherapeutics · 2015Review
- Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration.PloS one · 2014Article
- Baculovirus: an insect-derived vector for diverse gene transfer applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Review
- Plant-derived virus-like particles as vaccines.Human vaccines & immunotherapeutics · 2013Review
- Article
- Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors.Gene therapy · 2011Article
- Gene Therapy.Advances in biochemical engineering/biotechnologyReview
- Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications.Biotechnology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant baculoviruses (rBVs) are widely used as vectors for the production of recombinant proteins in insect cells. More recently, these viral vectors have been gaining increasing attention due to their emerging potential as gene therapy vehicles to mammalian cells. Their production in stirred bioreactors using insect cells is an established technology; however, the downstream processing (DSP) of baculoviruses envisaged for clinical applications is still poorly developed. In the present work, the recovery and purification of rBVs aiming at injectable-grade virus batches for gene therapy trials was studied. A complete downstream process comprising three steps--depth filtration, ultra/diafiltration and membrane sorption--was successfully developed. Optimal operational conditions for each individual step were achieved yielding a scalable DSP for rBVs as vectors for gene therapy. The processing route designed hereby presents global recovery yields reaching 40% (at purities over 98%) and, most importantly, relies on technologies easy to transfer to process scales under cGMP guidelines.
Indexed as
Identifiers
19340018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.